Alfa-epoietin and anaemia in gynaecological cancer.
The incidence and severity of anaemia in gynaecological cancer patients depends on several factors including age, histology and tumor stage, site of neoplasm and treatment. At present, two principal opinions are available for the management of chronic anaemia in cancer patients: blood transfusions and treatment with recombinant human Erythropoietin (rHuEPO). Clinical studies showed that rHuEPO can ameliorate chronic and chemotherapy-induced anaemia and reduce transfusions in patients with various malignant diseases. In this review we discuss the role of alfa-epoetin in the management of gynaecological and breast cancers.
Di Cocco
Barbara
B
Division of Medical Oncology, Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144 Rome, Italy.
Salesi
Nello
N
Fabi
Alessandra
A
Nardoni
Chiara
C
Ferretti
Gianluigi
G
Bossone
Giandominik
G
Ciccarese
Mariangela
M
Savarese
Antonella
A
Vecchione
Aldo
A
Cognetti
Francesco
F
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005833:Genital Neoplasms, Female / Q000097:blood* / Q000532:radiotherapy; D006801:Humans; D011788:Quality of Life; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin